Company Profile

Cytovation’s lead product, CyPep-1 is a first in class peptide consisting of 27 amino acids that is currently in pre-clinical development for the treatment of cutaneous warts caused by human papilloma virus (HPV) and has applications in other dermatological diseases. There are currently no prescription medicines available for the treatment of cutaneous warts and over-the-counter products often do not permanently remove the wart.

CyPep-1 rapidly and selectively targets HPV diseased cells, due to a negative charge on their cell membranes not found on healthy cells, rapidly killing the wart cells by disrupting the cell membrane and creating an immune response through the release of antigens which could lead to long-term ‘protection.’ CyPep-1 is an effective potential prescription treatment for warts that can potentially permanently eradicate the HPV virus. CyPep-1 has world-wide patent protection across the USA, Europe, Japan and China.